Csl Ltd has released a press release.
Research and Development Investor Briefing 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- CSL Full Year Statutory Accounts for the Year Ended 30/06/19
- Update on CSL transition to own distributor model in china
- Half Year Results Analyst Presentation
- Appendix 4D and Half Year Accounts
- CSL R&D Investor Briefing
Later from CSL
- CSL Statutory Accounts for the Half Year Ended 31/12/2019
- New Debt Facilities to Strengthen Maturity Profile
- Change in Leadership of CSLs Finance Function
- CSL to acquire LateStage Gene Therapy Candidate from uniQure
- Statutory Accounts for the Full Year Ended 30 June 2020
Follow CSL into a list and get an email when it puts out news.
Follow CSL